1 2 3 4 5 6

found Documents: 426

Announcements & Press Releases, Oncology / Immunology | 20 Jun 2016

Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer

2 items

Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study builds on encouraging data from initial small Phase II studies of savolitinib in combination with Tagrisso or Iressa in c-Met-am

Savolitinib Clinical Trials Summary (PDF)View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 13 May 2016

Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer

1 item

London: Friday, May 13, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has completed patient enrollment of FRESCO, its Phase III pivotal trial of fruquintinib (HMPL-013) in third-line locally advanced

Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer

Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer

Chi-Med to Participate in Two Healthcare Investor Conferences in May

Hutchison China MediTech Limited Announces Exercise of Overallotment Option

Chi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689

Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market

Chi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients

Final Prospectus

Pricing of U.S. Public Offering of ADSs

Hutchison China MediTech Limited Announces Pricing of U.S. Public Offering of ADSs

2015 Annual Report and Notice of Annual General Meeting

Repeat of Announcement of Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs

Hutchison China MediTech Limited Announces Launch of Potential U.S. Public Offering of ADSs

Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs

Chi-Med initiates sulfatinib Phase II clinical trial in thyroid cancer

Fourth Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

Final Results for the year ended 31 December 2015

Third Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

Initiation of HMPL-523 Phase I clinical trial in haematological cancer in Australia

Initiation of sulfatinib Phase III registration study in neuroendocrine tumour patients

US$105 million Shanghai land compensation agreement

Initiation of fruquintinib Phase III registration trial in non-small cell lung cancer

Second Public Filing of Registration Statement on Form F‑1 for potential Nasdaq Stock Market Listing

Chi-Med initiates sulfatinib U.S. clinical trials

Sulfatinib clinical results and fruquintinib-savolitinib combination preclinical results to be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference

Completion of Phase I clinical trial of novel Syk Inhibitor HMPL-523 for autoimmune diseases in healthy volunteers

Proof-of-concept study of fruquintinib in non-small cell lung cancer triggers milestone payment

Hutchison China MediTech Limited Files Registration Statement for Potential Nasdaq Stock Market Listing

Shareholders' Circular and Notice of Extraordinary General Meeting

Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma

Winner of International Company of the Year 2015, AIM

Fruquintinib Phase II clinical results in colorectal cancer to be presented at the 2015 European Cancer Congress

Second proof-of-concept trial of fruquintinib achieves its primary endpoint

Termination of Research & Development Alliance Agreement with Janssen Relating to HMPL-507 Project

Interim Results for the Six Months Ended 30 June 2015

Mitsui exchanges its shares in Hutchison MediPharma for shares in Chi-Med

20-year invention patent granted on Chi-Med's best selling prescription drug

Savolitinib (AZD6094) preliminary Phase Ib clinical data in lung cancer presented at the 2015 ASCO Annual Meeting

Positive fruquintinib proof-of-concept study results trigger payments from Lilly

The first proof-of-concept trial of fruquintinib achieves primary efficacy endpoint

Patient enrolment completion for fruquintinib's Phase II study in non-small cell lung cancer; Fruquintinib development moving rapidly in four parallel studies in non-small cell lung cancer, colorectal cancer and gastric cancer

Final Results for the year ended 31 December 2014

Hutchison Sinopharm and AstraZeneca China signed an exclusive distribution agreement on Seroquel® in China

Initiation of fruquintinib Phase III registration study in colorectal cancer

Drug R&D Update Briefing for Analysts and Investors on 17 October 2014

Chi-Med and Merck Serono sign co-promotion agreement

Patient enrolment completed ahead of schedule for fruquintinib's Phase II study in colorectal cancer

HMPL-004 NATRUL-3 interim analysis result

Interim Results for the Six Months Ended 30 June 2014